Schrodinger (SDGR) reported $256M in revenue for fiscal 2025, +23.3% year on year. That ranks #2561 by revenue among 2853 SEC filers and #264 in Healthcare. It posted a net loss of −$103M for the same year. Revenue has grown 20.0% a year on average since 2019 ($85.5M then). The fiscal 2025 balance sheet shows $726M in total assets and $231M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $256M | +23.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $143M | +8.0% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$167M | +$42.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$103M | +$83.9M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $13.9M | +$171M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.4M | −80.3% | FY20252025-12-31 |
| Total assetsAssets | $726M | −11.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $364M | −13.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $231M | +56.5% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $58.6M | −$60.0M | Open → |
| Q2 20262026-06-30 | $58.9M | $6.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Schrodinger, Inc.
- Ticker
- SDGR
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001490978
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Jushi HoldingsJUSH | $263M | −$68.6M |
| ArvinasARVN | $263M | −$81.0M |
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
| Lemaitre VascularLMAT | $250M | $57.7M |
| Arcus BiosciencesRCUS | $247M | −$353M |
| Keros TherapeuticsKROS | $244M | $87.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Schrodinger — Key figures |url=https://companiesranked.com/en/company/schrodinger |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Schrodinger — Key figures. CompaniesRanked. https://companiesranked.com/en/company/schrodingerBibTeX
@misc{companiesranked-en-company-schrodinger-2026,
author = {{CompaniesRanked}},
title = {{Schrodinger — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/schrodinger}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001490978-26-000010 · February 25, 2026
{{cite web |title=Schrodinger — Key figures — 10-K (0001490978-26-000010) |url=https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.